You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Owen Mumford has acquired the exclusive rights to Atomo's CE-marked HIV tests and will bring them to market in Europe under the Simplitude brand.
The initial focus will be on Zika and chikingunya, and will leverage iBio's antigen and antibody manufacturing capabilities for product prototype development.
Five Prime will use an IHC CDx to analyze the use of investigational drug candidates in patients with advanced gastric or gastroesophageal junction cancer.
Rainbow will offer Color's hereditary cancer and heart health genetic risk assessment tests to patients in Hong Kong.
Pro-Lab will shepherd Medicortex's kit through the regulatory processes in Canada and the UK, as well as clinically validate it. It will have exclusive rights to sell the kit in the two nations.
Sphingotec's proenkephalin and adrenomedullin biomarkers and Nexus Dx's Nexus IB 10 point-of-care testing platform will be merged under jointly owned holding company Polaris MediNet.
The partners will combine Chembio's DPP technology and biomarkers developed at Mass General for diagnostic tests for typhoid and febrile illness.
FIND is granting an award to Altona Dx, Cepheid, and the Bernhard Nocht Institute to develop an assay for Lassa virus. It also signed an MOU with the UK government to combat antimicrobial resistance.
Roche is developing an immunohistochemnistry assay for Pierre Fabre's oncology drug candidate, an antibody drug conjugate targeting insulin-like growth factor 1 receptor.
Under a collaboration with GeneDx, Boston Children's has rapidly sequenced the exomes of 20 NICU babies and have arrived at a likely diagnosis in around 85 percent.